Efficacy of the combined therapy with etanercept and methotrexat at the female patient with generalized pustular psoriasis and arthritis psoriasis after the therapeutic failure of two the TNF-α receptor inhibitors. Case study

Cover Page

Abstract


The article presents the clinical observation effectiveness of TNF-a inhibitor etanercept in patients with generalized pustular psoriasis and PsA, resistant to treatment by other drugs of this class. It presents the current recommendations for the management of patients with pustular psoriasis.

V. V. Vustina

Perm Regional Clinical Hospital, Department of Cardiology/Rheumatology

Author for correspondence.
Email: noemail@neicon.ru

Russian Federation

N. E. Grigoriadi

Perm Regional Clinical Hospital, Department of Cardiology/Rheumatology

Email: noemail@neicon.ru

Russian Federation

T. V. Korotayeva

Nasonova Research Institute of Rheumatology

Email: tatianakorotaeva@googlemail.com

Russian Federation

  1. Gelfand J.M., Gladman D.D., Mease P.J. et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005; 53: 573.
  2. Gladman D.D., Antoni C., Mease P. et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis 2005; 64 (Suppl. 2): 14-7.
  3. Мишина О.С., Коротаева Т.В., Стародубов В.И., Насонов Е.Л. Заболеваемость псориатическим артритом в Российской Федерации: тенденции на современном этапе и перспективы. Научно-практическая ревматология 2015 (53) 3: 251-257
  4. Sieper J., Van der Heijde D., Landewe R. et al. New criteria for in-flammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis International Society (ASAS). Ann. Rheum. Dis 2009; 68: 784-8
  5. Rudwaleit M., van der Heijde D., Landewé R. et al. The Assess-ment of Spondyloarthritis Inter-national Society classiication criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann. Rheum. Dis 70 (1), 25-31 (2011)
  6. Sabat R., Philipp S., Hölich C. et al. Immuno-pathogenesis of psoriasis. Exp. Dermatol 16 (10), 779-798 (2007).
  7. Mease P.J. Psoriatic Arthritis: update on pathophysiology, assessement and management Ann Rheum Dis 2011; 70 (suppl): 77-84.
  8. Ritchlin C.T. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2005; 17: 406-12.
  9. Husted J.A., Gladman D.D., Farewell V.T., Cook R.J. Health-related quality of life of patients with psoriatic arthritis: a compari-son with patients with rheumatoid arthritis. Arthritis Rheum 2001; 45: 151-8.
  10. Ritchlin C.T., Kavanaugh A., Gladman D.D. et al. Treatment rec-ommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68 (9): 1387-1394.
  11. Mease P.J., Kivitz A.J., Burch F.X. et al. Etanercept treatment of psoriatic arthritis: safety, eficacy, and effect on disease progres-sion. Arthritis Rheum 2004; 50 (7): 2264-2272.
  12. Atteno M., Peluso R., Costa L. et al. Comparison of effectiveness and safety of inliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 2010; 29 (4): 399-403.
  13. Бадокин В.В. Перспективы применения ингибиторов ФНО-α при псориазе и псориатическом артрите // Клиническая фармакология и терапия 2005. № 14. С. 76-80
  14. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., Salonen D., Rubenstein J., Sharp J.T., Tsuji W. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004 Jul; 50 (7): 2264-72
  15. Smolen J.S., Ramiro S. et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacologicaltherapies: 2015 update. Ann Rheum Dis 2016; 75: 499-510
  16. Coates L. et al. GRAPPA Treatment Recs for PsA. Arthritis Rheum DOL 10.1002/art.39573
  17. Ramiro S., Smolen J.S., Landewé R. et al. Pharmacological treat-ment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2016; 75: 490-498
  18. Федеральные клинические рекомендации по ведению больных псориатическим артритом. Москва, 2015
  19. Коротаева Т.В. Прогресс в лечении псориатического артрита. Фарматека 2015; 7 (300): 21-27
  20. Gottlieb A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J. Am. Acad. Dermatol. 58, 851-864 (2008)
  21. Chang C.A. et al. Management of psoriatic arthritis from the view of the dermatologist.Nat. Rev. Rheumatol. 7, 588-598 (2011); published online 13 September 2011; doi:10.1038/ nrrheum.2011.125
  22. Федеральные клинические рекомендации по ведению больных псоризом. Москва, 2015
  23. Rinaldi F., Provenzano G., Termini A., Spinello M., La S.F. Long term infliximab treatment for severe psoriatic arthritis: evidence of sustained clinical and radio-graphic response. Ann Rheum Dis 2005; 64: 1375-6
  24. Rodgers M., Epstein D., Bojke L. et al. Etanercept, inliximab, and adalimumab for the treatment of psoriatic arthri-tis: a systematic review and economic evaluation. Health Technol Assess. 2011; 15 (10): i-xxi, 1-329
  25. Kristensen L.E., Gülfe A., Saxne T. and Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008 67: 364-369 originally published online July 20, 2007 doi: 10.1136/ard.2007.073544
  26. Коротаева Т.В. Иммуногенность, вызванная биологическими препаратами при лечении псориаза и псориатического артрита: взгляд на проблему. Современная ревматология 2015; 9 (4): 13-19
  27. Coates L.C., Helliwell P.S. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken). 2010; 62: 965-969. Saber T.P., Ng C.T., Renard G. et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010; 12 (3): 94-98
  28. SAAD P.M., SYMMONS P., NOYCE D., ASHCROFT. Risks and Benefits of Tumor Necrosis Factor-α Inhibitors in the Manage-ment of Psoriatic Arthritis: Systematic Review and Metaanalysis of Randomized Controlled Trials J Rheumatol 2008; 35: 883-90
  29. Saad A.A., Ashcroft D.M., Watson K.D. et al. Eficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology 2010; 49 (4): 697-705. doi: 10.1093/rheumatology/kep423
  30. Woolacott N.F., Khadjesari Z.C., Bruce I.N., Riemsma R.P. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review. Clin Exp Rheumatol 2006 Sep-Oct; 24 (5): 587-93
  31. Papoutsaki M., Costanzo A. Treatment of psoriasis and psoriatic arthritis. BioDrugs. 2013 Jan; 27 Suppl 1: 3-12. doi: 10.1007/BF03325637
  32. Benjegerdes K.E., Hyde K., Kivelevitch D., Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis: Targets and Therapy 2016; 6: 131-144
  33. Robinson A. et al. Treatment of pustular psoriasis: From the Medical Board of the National Psoriasis Foundation. Published online May 21, 2012.0190-9622/$36.00. by the American Academy of Dermatology, doi:10.1016/j. jaad.2011.01.032

Views

Abstract - 80

PDF (Russian) - 29

Refbacks

  • There are currently no refbacks.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies